With the extent of the recent Ebola virus disease (EVD) epidemic in West Africa (including >28 000 cases and ≤17 000 survivors), many aspects of Ebola virus have become clearer, including acute manifestations, sequelae, and the possibility of relapse and persistence.
Ebola virus was recovered from the cerebrospinal fluid (CSF) at higher levels than from the blood, indicating viral replication in the CNS. 5 This case reveals the need to determine the role of the CNS as a potential reservoir for Ebola virus after initial clinical recovery.
Methods | To investigate potential Ebola virus persistence in the CNS, we undertook a systematic study of CSF samples from patients who survived EVD (hereinafter referred to as EVD survivors). Through partnership between the National Institutes of Health and Liberia's Ministry of Health, the A subset of EVD survivors (n = 165) underwent evaluation by neurologists as part of this study. Survivors who reported coma, delirium, or meningitis during acute EVD, who reported new neurologic symptoms since recovery, and who had neurologic abnormalities on examination were selected as candidates for lumbar puncture (LP). These survivors (n = 22) were informed about LP using illustrated flip charts; those who decided to proceed were screened for eligibility (n = 18). Eligibility criteria included age 18 to 60 years, positive for Ebola virus antibody, no new neurologic findings at time of LP, negative for human immunodeficiency virus antibody, no recent seizure or head trauma, no use of nonsteroidal anti-inflammatory drugs, no papilledema, and normal results of coagulation studies.
For patients who met criteria and signed informed consent (n = 8), LPs were performed in standard fashion by operators in full personal protective equipment (B.J.B., J.D., and B.R.S.). Samples were collected from December 15 to 18, 2015. Each LP sample collected included 15 to 20 mL of CSF. Fluid was analyzed for Ebola viral RNA by reverse transcriptase-polymerase chain reaction (RT-PCR) at the Liberian Institute for Biomedical Research laboratory. The RT-PCR systems used to detect nucleoprotein and glycoprotein gene targets included ABI 7500 (Applied Biosystems) and GeneXpert IV (Cepheid); the level of detection for the GeneXpert assay is 232 copies/mL. 6 The CSF cell count was assessed using a hemocytometer. Glucose and protein levels were measured using a semiautomated clinical chemistry analyzer (Excel; Stanbio Laboratory). 
OBSERVATION

Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab
Alemtuzumab is a humanized monoclonal antibody recently approved for relapsing-remitting multiple sclerosis (MS) treatment. It is highly effective at reducing relapse rate, improving disability outcomes, and decreasing magnetic resonance imaging activity. 1 Adverse events include infusion-related reactions, infections, and secondary autoimmune disorders.
1,2
We report 2 cases of MS with early neutropenia due to alemtuzumab, an adverse event not previously described, to our knowledge. Both patients signed informed consent.
Report of Cases | Case 1. In a man in his early 20s with relapsingremitting MS, treatment with interferon beta-1a failed, and John Cunningham virus seropositivity developed while the patient was receiving natalizumab intravenously. After an 8-week washout, he was switched to fingolimod and experienced severe rebound 8 weeks later. The patient was then treated with methylprednisolone and plasma exchange, and 17 weeks after the last dose of fingolimod, he received alemtuzumab. At that time, he had a normal white blood cell (WBC) count of 9150/μL (absolute neutrophil count [ANC], 7192/μL; lymphocytes, 1006/μL; to convert WBC, ANC, and lymphocyte counts to ×10 9 /L, multiply by 0.001). Four weeks after standard alemtuzumab induction (12 mg/day for 5 days), severe neutropenia developed (WBC count, 600/μL; ANC, 470/μL) (Figure) . After granulocyte-stimulating factor (300 mg/day for 72 hours) his neutropenia resolved, but he had a fever and severe impetiginized acne of the face and chest, concomitant with type 1 herpes simplex virus infection, despite acyclovir prophylaxis (400 mg twice a day). He had a poor response to intravenous minocycline and increased acyclovir (800 mg 4 times a day), leading to addition of vancomycin, fluconazole, and later levofloxacin. In May 2016, a second infusion of alemtuzumab (12 mg/day for 3 days) did not induce neutropenia. His lowest ANC was 2752/μL 3 weeks after infusion. No further MS activity has been observed.
Case 2. In a woman in her mid-20s with relapsing-remitting MS, treatment with interferon beta-1a and teriflunomide failed. She was treated with fingolimod for 13 months, but radiologic and clinical disease activity persisted. She was switched to a standard dose of alemtuzumab (12 mg/day for 5 days) after 10.4 weeks of fingolimod washout. Prior to infusion, her WBC count was normal (WBC, 4900/μL; ANC, 2494/μL; lymphocytes, 1832/μL). Six weeks after treatment, febrile neutropenia and sinusitis developed (WBC, 1000/μL; ANC, 300/μL) (Figure) . The patient received intravenous antibiotics combined with granulocyte-stimulating factor (300 mg/day for 72 hours), and her ANC normalized. A week later, her blood cell count dropped again (WBC, 1400/μL; ANC, 700/μL); granulocytestimulating factor was administered for 3 days leading to rapid recovery. Five weeks after the second infusion of alemtuzumab (12 mg/day for 3 days), she had transient neutropenia (ANC, 398/μL) lasting 6 days with no further MS activity detected.
Discussion | We know of no reported MS cases of alemtuzumab infusion-related neutropenia. During phase 3 trials, 1 there were Case 2
B
Changes in total white blood cell (WBC) count, absolute neutrophil count (ANC), and lymphocyte count over 3 months after alemtuzumab infusion; after 90 days, cell count remained stable. A, Case 1 received 300 mg of granulocyte-stimulating factor (GSF) 32 days after alemtuzumab infusion. B, Case 2 required 2 cycles of 300 mg of GSF 46 days and 58 days after infusion. To convert WBC, ANC, and lymphocyte counts to ×10 9 /L, multiply by 0.001. 
